Very solid earnings growth and appears to be
excellent value. Breaking towards 52 week highs in
preparation of earnings report coupled with analyst coverage
due out. The recent volume suggests upward potential
5 qtrs record revenues, FDA
approvals, new products, ownership and board members from
GDT and others....
Looks to be good growth
stock value and/or near/intermediate buy out
not talking about all of bard just the division
we had mentioned earlier .. i guess no news is good
news .. heard about a large international conglomerate
looking into the deal also .. no names mentioned .. i
know that the price is over 50 million and has other
factors attached ..
not sure as to the rules of the sec on rumors but
have heard a lot of whistles concerning the price and
i am very surprised that none of this is being
reported .. hmm four new data information positngs at its
headquarters .. lesion .. have you tried company sleuth .. so
is BSX the highest profile of the four rumored
suitors? no one talks names down here .. sigh
seems as if every time there are "early
retirements" wall street goes nuts about the company's
prospects .. have looked hi and low for the cardiopulmonary
info .. they are keeping it pretty quiet .. sighs ..
personally .. i don't think this company is keeping up in
terms of acquistions with the big players .. seems to
be more content with a slow steady stock price rise
.. still i'm not sure why they sold divisions rather
than spinning them off ..